Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial

Amrousy, Doaa El; Hassan, Syed Moin; Ashry, Heba El; Yousef, Mohamed; Hodeib, Hossam

doi:10.4103/sjg.sjg_438_17

Cited by 34 publications

(59 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intake of 1 pearl of vitamin D3 containing 50,000 IU per week for 9 weeks increased serum 25(OH) vitamin D3. The same results have been reported by previous work assessing the effect of vitamin D on IBS patients [23][24][25].…”

Section: Discussionsupporting

confidence: 89%

“…Moreover, studies demonstrated that vitamin D deficiency is related to symptoms of psychological disorders [21,22]. It goes without saying that the mechanism of the effect of vitamin D on IBS symptoms is not quite clear in recent trials [23][24][25]. In this study, we hypothesized that DOI: 10.1159/000506149 vitamin D may improve clinical symptoms by ameliorating mental state [21,26] and by anti-inflammatory effects [27,28].…”

Section: Introductionmentioning

confidence: 90%

See 1 more Smart Citation

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 – A Randomized Clinical Trial

et al. 2020

View full text Add to dashboard Cite

Objectives: This study aimed to evaluate whether vitamin D deficiency is associated with the severity of symptoms of irritable bowel syndrome (IBS) patients. Stress and gut inflammation can increase the serum level of corticotropin-releasing hormone (CRH) and interleukin-6 (IL-6), leading to a change in bowel movements. The aim of this study was to evaluate the anti-inflammatory and psychological effects of vitamin D3 supplementation on the symptom improvement of patients with a diarrhea-predominant form of IBS (IBS-D). Methods: Eighty-eight IBS-D patients (age: 18–65 years) based on Rome IV criteria who suffered from vitamin D deficiency and/or insufficiency were enrolled in this randomized, placebo-controlled trial from February 2017 to May 2018 at Rasoul-e-Akram Hospital, Tehran, Iran. Participants were randomly divided into two groups. The intervention group received 50,000 IU vitamin D3 weekly and the control group received a placebo for 9 weeks. All patients received Mebeverine 135 mg twice a day besides supplementation. The IBS Severity Score System (IBS-SSS), serum 25(OH) vitamin D3, CRH, and IL-6 were measured before and after interventions. Results: Seventy-four patients completed the study. The severity of IBS symptoms (p < 0.01) and IL-6 (p = 0.02) decreased significantly in the intervention group as compared to the control group, but there was no significant difference in the serum level of CRH. Also, in the treatment group, IBS-SSS and IL-6 were significantly reduced at the end of the study from baseline (p < 0.01 and p < 0.03, respectively). Conclusion: Our findings indicate that vitamin D3 supplementation can modulate the serum level of CRH and IL-6 and can improve symptoms in IBS-D patients. Vitamin D3 supplementation should be considered in IBS-D patients who suffer from vitamin D deficiency and/or insufficiency.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 90%

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 – A Randomized Clinical Trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This was in accordance with the results reported in another Egyptian study conducted on 112 adolescents which reported a significant improvement in the clinical status of patients with IBS who received vitamin D compared to the placebo group. 8 In an Iranian study, there was a statistically significant improvement (p < 0.05) in most IBS symptoms among patients receiving 50.000 IU vitamin D 3 every two weeks for 6 months 1 . Contrary to these results, IBS symptoms were not significantly improved in an English pilot trial conducted on 51 patients with IBS after 12 weeks of daily 3000 IU vitamin D 3 supplementation.…”

Section: Resultsmentioning

confidence: 94%

“…Results showed that the baseline difference between the intervention and the control groups regarding IBSSSS was statistically insignificant (p=0.078). However, after the intervention, patients receiving vitamin D 3 7,8 the mechanism behind this is still a controversy. 12 The present study was conducted to assess the effect of oral vitamin D 3 supplementation (Cholecalciferol) on gastrointestinal symptoms in patients with IBS.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Vitamin D3 (Cholecalciferol) Supplementation on Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome Attending El-Mahsama Family Practice Center, Ismailia, Egypt: A Randomized Clinical Trial

Zeid

Ezzeldeen

Khattab

et al. 2020

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

Background: Irritable bowel syndrome (IBS) is a functionalgastrointestinal condition, in which patients suffer from abdominal pain, bloating, and change in bowel habits. Some researchers examined the potential therapeutic role of vitamin D3 (Cholecalciferol) to alleviate symptoms of IBS, however, the outcomes of their studies werecontroversial. Objective: to assess the effect of vitamin D3 supplement on gastrointestinal symptoms in patients suffering from irritable bowel syndrome. Methods: a double-blinded, randomized, placebo-controlled trial. Eighty patients with IBS attending the family practice center in El-Mahsama, Ismailia, Egypt were recruited, after applying inclusion and exclusion criteria. The study participants were allocated randomly into two groups, (1) the intervention and (2) the control group. The intervention group received 4000 IU of vitamin D3 orally and the control group received a placebo of edible paraffin orally. Both groups received their assigned treatment daily for 12 weeks. Irritable bowel syndrome symptom severity score (IBSSSS) was assessed at baseline and after 12 weeks. Results: IBSSSS was significantly reduced in the intervention group (114.36 ± 67.36) after 12 weeks compared to the control group (292.13 ± 74.77) (p<0.001). Regarding IBSSSS difference, patients receiving vitamin D were found to have significantly higher score difference (-164.72 ± 67.77) than participants who took the placebo (-12.13 ± 50.78) (p<0.001). Conclusion: Patients suffering from IBS felt better and their gastrointestinal symptomsimproved after taking vitamin D3 supplementation.

show abstract

Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial

Williams

Corfe

2021

Eur J Nutr

View full text Add to dashboard Cite

Purpose Several small trials suggest a benefit of vitamin D supplementation in irritable bowel syndrome (IBS). The generalisability of these reports is limited by their design and scale. This study aimed to assess whether vitamin D supplementation improved IBS symptoms in a UK community setting. Methods This was a randomised, double-blind, placebo-controlled study. Participants were recruited from the community in winter months between December 2017 and March 2019. 135 participants received either vitamin D (3,000 IU p.d.) or placebo for 12 weeks. The primary outcome measure was change in IBS symptom severity; secondary outcomes included change in IBS-related quality of life. Results The participants were analysed on an intent-to-treat basis. 60% of participants were vitamin D deficient or insufficient at baseline. Although vitamin D levels increased in the intervention arm relative to placebo (45.1 ± 32.88 nmol/L vs 3.1 ± 26.15 nmol/L; p < 0.001). There was no difference in the change of IBS symptom severity between the active and placebo trial arms (− 62.5 ± 91.57 vs – 75.2 ± 84.35, p = 0.426) over time. Similarly there was no difference between trial arms in τhe change in quality of life (− 7.7 ± 25.36 vs – 11.31 ± 25.02, p = 0.427). Conclusions There is no case for advocating use of vitamin D in the management of IBS symptoms. The prevalence of vitamin D insufficiency suggests routine screening and supplementation should be implemented in this population for general health reasons. This trial was retrospectively registered with ISRCTN (ISRCTN13277340) on 24th April 2018 after recruiting had been initiated.

show abstract

Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial

Cited by 34 publications

References 30 publications

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 – A Randomized Clinical Trial

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 – A Randomized Clinical Trial

Effect of Vitamin D3 (Cholecalciferol) Supplementation on Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome Attending El-Mahsama Family Practice Center, Ismailia, Egypt: A Randomized Clinical Trial

Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial

Contact Info

Product

Resources

About